Introduction
============

Dysregulation of mineral homeostasis due to failing kidney function leads to decreased renal phosphate excretion, elevated fibroblast growth factor 23 level, and reduced synthesis of calcitriol. These changes lead to consistent secretion of parathyroid hormone (PTH) contributing to the development of parathyroid hyperplasia and secondary hyperparathyroidism (SHPT) in end-stage renal disease. SHPT with elevated calcium and phosphate levels contributes to the development of renal osteodystrophy, erythropoietin resistance, vascular calcification, and left ventricular hypertrophy. These clinical features are strongly associated with increased morbidity and mortality in dialytic end-stage renal disease population.[@b1-dddt-10-2211]--[@b4-dddt-10-2211] It is therefore critical to maintain optimal level of PTH in these patients. However, because of the complicated problems of lowering PTH with simultaneously controlling imbalanced serum levels of calcium and phosphate, traditional therapies of phosphate binders and vitamin D analogues for managing SHPT have all too often led to clinical problems, including hypercalcemia, hyperphosphatemia, and refractory hyperparathyroidism or over-suppression of PTH.[@b5-dddt-10-2211]

One of the newer treatment options for SHPT is cinacalcet which increases the sensitivity of the calcium-sensing receptor (CaSR) on the parathyroid gland cells to extracellular calcium,[@b6-dddt-10-2211] resulting in a decreased calcium set point and circulating PTH levels.[@b6-dddt-10-2211]--[@b8-dddt-10-2211] The cinacalcet treatment resulted in 41% of SHPT patients achieving PTH and Ca × P levels recommended by the Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines[@b9-dddt-10-2211] whereas fewer than 10% of the patients treated with phosphate binders and vitamin D analogs reached optimal control.[@b10-dddt-10-2211] Moreover, cinacalcet reduced the risk of parathyroidectomy by 91%.[@b11-dddt-10-2211] Cinacalcet treatment is effective to the extent that it can be utilized as an alternative to surgical intervention in some patients.[@b12-dddt-10-2211],[@b13-dddt-10-2211] Despite the overall response to cinacalcet being promising in a number of clinical trials,[@b14-dddt-10-2211]--[@b16-dddt-10-2211] the therapeutic efficacy has a significant inter-individual variability of 12.1%--46% PTH reduction, representing drug resistance.[@b17-dddt-10-2211]--[@b21-dddt-10-2211] The factors associated with the drug resistance include delayed therapy, persistent hyperphosphatemia, nodular hyperplasia,[@b22-dddt-10-2211] and reduced expression of CaSR and vitamin D receptor (VDR).[@b23-dddt-10-2211]--[@b25-dddt-10-2211] In particular, genetic polymorphisms affecting CaSR and VDR expression have been considered as factors for drug resistance. The genetic polymorphism of *CASR* Arg990Gly (c.2968A \> G, rs1042636) was associated with different cinacalcet response.[@b26-dddt-10-2211] Several other studies[@b27-dddt-10-2211]--[@b29-dddt-10-2211] on *CASR* presented the possible association of *CASR* rs1042636 and rs2221266 polymorphisms with PTH level difference. *VDR* gene polymorphisms of rs7975232 (*Apa 1*), rs731236 (*Taq 1*), and rs1544410 (*Bsm 1*) were also associated with PTH regulation.[@b30-dddt-10-2211]--[@b32-dddt-10-2211] These studies presented the clinical importance of genetic polymorphisms in PTH regulation. However, the results available so far show limited evidence for genetic polymorphisms associated with cinacalcet response involving a small number of patients and not including phosphate and bone regulation-related genes in PTH homeostasis. Thus, we aimed to evaluate the frequency of variants of study genes related to PTH regulation and the association between SNPs and haplotypes of genes and cinacalcet response in Korean SHPT patients on dialysis.

Methods
=======

Study subjects
--------------

Study patients were selected from a tertiary university hospital in Seoul, Korea, between June 2011 and July 2014. Patients with a diagnosis of SHPT based on intact parathyroid hormone (iPTH) \>300 pg/mL were included in this study. The patients were over 18 years and have been treated by cinacalcet for more than 3 months. All these patients were on either hemodialysis or peritoneal dialysis, receiving optimal medical therapy in the form of dietary restriction, phosphate binders, or vitamin D sterols. The main exclusion criteria were serious concomitant hepatic disease, active cancers, or taking strong CYP3A4 inhibitors, such as itraconazole, clarithromycin, diltiazem, and verapamil.

The study complies with the Helsinki Declaration and was approved by the Ethics Committee of the Seoul National University Hospital (IRB \#: H-1408-082-604). Written informed consents were obtained from all patients.

Data collection
---------------

Demographic information on the cause of chronic kidney disease (CKD), mode and duration of dialysis, concomitant drugs, and biochemical parameter levels of serum calcium, phosphorus, alkaline phosphatase, iPTH, creatinine, estimated glomerular filtration rate using Modification of Diet in Renal Disease equation, albumin, and hemoglobin at the start and during 3 months of cinacalcet treatment was obtained. Responders and nonresponders were grouped by their serum iPTH changes. Nonresponders were grouped as the patients whose iPTH levels increased even after 3 months of cinacalcet treatment.[@b33-dddt-10-2211],[@b34-dddt-10-2211] Otherwise, those patients whose iPTH values showed any reduction during the period of 3-month cinacalcet treatment were defined as responders.

Serum calcium and phosphate levels were measured by standard methods; iPTH was measured using a double-antibody immunoradiometric assay for the quantitative determination of intact biological chain of 84 amino acids of PTH in human serum (ELSA PTH, Cisbio Bioassays, Codolet, France). Serum calcium was reported as albumin corrected values throughout this research.

Genotype selection and analysis
-------------------------------

Twenty-five SNPs in nine genes which are previously known as related to calcium, phosphate, and bone metabolism were selected from the results of previous literatures and databases. Of these genes, *CASR*[@b26-dddt-10-2211]--[@b29-dddt-10-2211],[@b35-dddt-10-2211]--[@b37-dddt-10-2211] and *VDR*[@b30-dddt-10-2211]--[@b32-dddt-10-2211],[@b38-dddt-10-2211],[@b39-dddt-10-2211] involved in calcium regulation; *FGFR1*,[@b40-dddt-10-2211],[@b41-dddt-10-2211] *KL*,[@b42-dddt-10-2211] *RGS14*,[@b43-dddt-10-2211],[@b44-dddt-10-2211] and *SLC34A1*[@b45-dddt-10-2211] related to phosphate serum concentration; and *ALPL*,[@b46-dddt-10-2211],[@b47-dddt-10-2211] *NR4A2*,[@b48-dddt-10-2211],[@b49-dddt-10-2211] and *PTHLH*[@b50-dddt-10-2211]--[@b53-dddt-10-2211] related to bone formation were evaluated. Peripheral blood samples were collected in ethylenediaminetetraacetic acid (EDTA) containing tubes and stored at −80°C before DNA isolation. The SNaPshot assay was performed according to the manufacturer's instructions (ABI PRISM SNaPShot Multiplex kit, Thermo Fischer Scientific, Waltham, MA, USA). [Table S1](#SD1-dddt-10-2211){ref-type="supplementary-material"} shows the included SNPs and the primer sets and melting temperature used for the SNaPshot assay. Twenty-four studied SNPs of *CASR*, *VDR*, *FGFR1*, *KL*, *ALPL*, *RGS14*, *NR4A2*, and *PTHLH* were in Hardy--Weinberg Equilibrium, but *SLC34A1* rs3812035 was not. Thus, association analysis of *SLC34A1* was excluded.

Statistical analysis
--------------------

The Hardy--Weinberg Equilibrium of each SNP was tested using the goodness-of-fit chi-square test to compare the expected frequencies of genotypes in controls; SNPs with *P*\>0.05 were considered to be in Hardy--Weinberg Equilibrium. The independent-samples *t*-test and Mann--Whitney test were used to determine the differences between parametric and nonparametric characteristics of patients and biochemical parameter changes. The chi-square or Fisher's exact test was performed to assess the difference between categorical variables of the patient characteristics. Unconditional logistic regression analysis and chi-square or Fisher's exact test were used to evaluate the frequency analysis of polymorphisms of the genes and the relationships between different genotypes and cinacalcet response. Statistical analysis was carried out using IBM SPSS Statistics 21.0 for Windows (SPSS Inc., IBM Corporation, Armonk, NY, USA). Haplotypes and haplotype frequencies were calculated using Haploview software (version 4.2, Massachusetts Institute of Technology, Cambridge, MA, USA). The haplotype with *P*\<0.05 was considered statistically significant.

Results
=======

Patient data
------------

A total of 70 dialysis patients with SHPT were included in the biochemical parameter analysis. Baseline characteristics were well balanced between the responders and nonresponders except for baseline calcium levels (*P*=0.001). The baseline iPTH for 68 patients was 622 (300--1,493) pg/mL versus 601 (316--1,183) pg/mL (*P*=0.375) for responders versus nonresponders, respectively. The parathyroid gland hyperplasia or adenomatous state did not differ between two groups (*P*=0.726). The amount of vitamin D (calcitriol or paricalcitol) taken by the patients (*P*=0.116) and the number of patients on phosphate binders and vitamin D analogues were not different between the two groups (*P*=0.116 and *P*=1.000, respectively) ([Table 1](#t1-dddt-10-2211){ref-type="table"}). The maintenance dose of cinacalcet ranged from 12.5 to 100 mg per day, depending on patient's status. The dose was higher in nonresponders: responders 25 (12.5--75) mg/day versus nonresponders 50 (25--100) mg/day (*P*\<0.001).

Biochemical parameter changes
-----------------------------

The biochemical parameter changes between baseline and 3-month treatment are summarized in [Table 2](#t2-dddt-10-2211){ref-type="table"}. Cinacalcet significantly reduced serum iPTH levels in 53 responders. The percent iPTH changes between baseline and 3-month treatment were −42.29 (−97.41 to 9.23) % versus 6.16 (0.90 to 45.25) % in responders versus nonresponders, respectively (*P*\<0.001). At 3-month treatment, 39.6% (21/53) of responders had an iPTH level below 300 pg/mL, the level recommended by the K/DOQI guidelines.[@b9-dddt-10-2211] The percent change of serum calcium concentration at 3-month treatment was −5.75 (−25.67 to 15.81) % in responders compared to −7.13 (−19.09 to 1.67) % in nonresponders (*P*=0.182). The percent change of serum phosphorus reduction in responders was −9.84 (−69.23 to 69.43) % compared to −8.42 (−33.33 to72.43) % in nonresponders (*P*=0.170).

Frequency analysis of genetic polymorphisms
-------------------------------------------

The loci, allele, and minor allele frequency (MAF) results are summarized in [Table 3](#t3-dddt-10-2211){ref-type="table"}. The observed MAFs in *CASR* rs1042636 and rs1802757 were 45.8% and 35.8%, respectively. *VDR* rs7975232 (*Apa 1*) and rs1544410 (*bsm 1*) were 16.0% and 6.3%, respectively, whereas rs2228570 (*Fok 1*) was 38.2%.

Association with cinacalcet response
------------------------------------

### Association of 24 SNPs with iPTH

The association of 24 SNPs with cinacalcet response was evaluated ([Table 4](#t4-dddt-10-2211){ref-type="table"}). The chi-square test showed that *CASR* rs1042636 had a significant difference in genotype frequencies between responder and nonresponders (*P*=0.036) but the MAF was not significant (*P*=0.075). The chi-square test also proved that *CASR* rs1042636 had a significant association with cinacalcet response (odds ratio \[OR\]: 0.267, *P*=0.035) in the dominant genetic model ([Table 5](#t5-dddt-10-2211){ref-type="table"}). Unconditional logistic regression analysis showed that *CASR* rs1042636 (OR: 0.074, *P*=0.025) (95% confidence interval \[CI\]: 0.008--0.721) and rs1802757 (OR: 8.625, *P*=0.042) (95% CI: 1.077--69.075) had an association with the cinacalcet response in the genotype model, indicating that the A to G substitution of rs1042636 decreased the risk of nonresponse by 93%, whereas the C to T substitution of rs1802757 increased the risk of nonresponse by approximately eight times. After adjusting for age, sex, and baseline calcium level, *CASR* rs1042636 (OR: 0.066, *P*=0.027) and rs1802757 (OR: 10.532, *P*=0.042) were associated with cinacalcet response.

### Association of *CASR* haplotypes with iPTH

The distribution of haplotypes was constructed for three genes and assessed for the association with the cinacalcet response. Linkage disequilibrium structures were designated by the *D*' value shown in [Figure 1](#f1-dddt-10-2211){ref-type="fig"}. Each of *CASR*, *VDR*, and *ALPL* genes included one haplotype block. The correlation coefficient (*r*^2^) between rs1042636 and rs1802757, rs1042636 and rs10190, and rs1802757 and rs10190 was 0.68, 0.77, and 0.87, respectively, and showed high correlations. The *CASR* haplotypes of GCC (OR: 0.355, *P*=0.015) and ATT (OR: 2.769, *P*=0.014) were associated with cinacalcet response. With regard to the haplotypes of *VDR* and *ALPL*, no significant association with cinacalcet response was found ([Table 6](#t6-dddt-10-2211){ref-type="table"}).

### Association of *CASR* genotypes with biochemical parameters

The associations between *CASR* genotypes and biochemical parameter changes were evaluated in 70 patients. The parameters showed that 3-month cinacalcet treatment lowered overall levels of serum calcium, −6.64 (−19.09 to 15.81) mg/dL, phosphate, −8.13 (−43.69 to 69.43) mg/dL, and Ca × P, −12.22 (−44.87 to 68.70) mg^2^/dL^2^ but the level of alkaline phosphatase, 2.36 (−28.48 to 146.58) mg/dL was increased. None of the genotypes of *CASR* was associated with the biochemical parameter changes ([Table S2](#SD2-dddt-10-2211){ref-type="supplementary-material"}).

Discussion
==========

In this study, the genotype frequencies of the SNPs related to PTH regulation and the association with cinacalcet response were evaluated. The observed MAFs in *CASR* rs1042636 and rs1802757 were double the reported frequency in HapMap[@b54-dddt-10-2211] whereas *VDR* rs7975232 (*Apa I*) and rs1544410 (*bsm I*) showed a lower frequency than that of HapMap. The rs2228570 (*Fok 1*) showed a similar frequency. Furthermore, the novel findings of our study are that genetic polymorphisms of *CASR* rs1802757 besides rs1042636 and haplotypes of rs1042636, rs10190, and rs1802757 were significantly associated with cinacalcet response. The gain of function nonsynonymous SNP of rs1042636, which is frequently found in the Asian population (MAF: Han Chinese 52.3%, Japanese 55.8%)[@b54-dddt-10-2211] results in different functionality[@b55-dddt-10-2211] and showed the consistent result with the previous study by Rothe et al.[@b26-dddt-10-2211] The study suggested that an Asian dialysis patient carrying a homozygous (G/G) variant of *CASR* rs1042636 showed significant iPTH reduction after 2-month cinacalcet treatment compared to another six patients having different genotypes. Several other studies[@b27-dddt-10-2211]--[@b29-dddt-10-2211] on *CASR* also presented the possible association of *CASR* rs1042636 with PTH level difference. However, the functionality of rs1802757 which is located in 3′ untranslated region (UTR) has not been well documented. We can assume that the rs1802757 influences the microRNAs which have the binding sites within 3′UTR, and can decrease gene expression of various mRNAs.[@b56-dddt-10-2211],[@b57-dddt-10-2211] Other studies presented that CaSR activated by calcimimetics decreased PTH--mRNA stability through the posttranslational modification of the PTH--mRNA binding protein AUF1.[@b58-dddt-10-2211] The rs1802757 can be investigated further via similar mechanism. In particular, the SNPs of rs1042636 and rs1802757 and haplotypes of GCC and ATT occurred at high frequencies of 45.8%, 35.9%, 52.9%, and 37.5%, respectively; in our result, the impact of these variants should not be negligible among Asians.

The regulation of PTH secretion and synthesis involves a multitude of pathways.[@b59-dddt-10-2211] However, in our study, the SNPs of genes other than *CASR* seemed not to correlate with cinacalcet response. Studies of *Casr* and *Vdr* knockout mice can explain part of our results. VDR-deficient mice which developed severe SHPT could be corrected by stabilizing serum calcium concentrations,[@b60-dddt-10-2211] whereas CaSR-deficient mice with SHPT were not corrected by elevated serum calcium and vitamin D levels and normal serum phosphorus,[@b61-dddt-10-2211] which demonstrates that CaSR is the major regulator of PTH secretion and bone abnormalities.[@b62-dddt-10-2211] Thus, other genes related to phosphate and bone metabolism do not have much effect on the PTH regulation by cinacalcet.

The maximum dose of cinacalcet approved in Korea is 100 mg/day and the higher titration dose did not control the PTH level in nonresponders. Previous studies suggested that early response to cinacalcet determined the effectiveness of cinacalcet treatment.[@b63-dddt-10-2211],[@b64-dddt-10-2211]

Therefore, our study can suggest that CKD patients who carry T allele of rs1802757 and/or ATT haplotype of rs1042646, rs10190 and rs1802757 have high risk of cinacalcet treatment failure and might be candidates for the parathyroidectomy. There have been pharmacoeconomic issues about the indefinite long-term cinacalcet treatment versus one-time surgery. The research in the 5 European countries by Iannazzo et al[@b65-dddt-10-2211] proved that cinacalcet treatment was beneficial when compared to the standard therapy of vitamin D analogues in cost-effectiveness and cost utility model compared to standard therapy of vitamin D analogs. Komaba et al[@b66-dddt-10-2211] presented that cinacalcet was cost-effective in 99.9% of the Monte Carlo simulations in parathyroidectomy ineligible patients, but only 0.9% of the simulations in parathyroidectomy eligible patients. Thus, nonresponders to cinacalcet treatment can have minimal cost-effectiveness compared to surgery in economic issues.

SHPT patients are highly vulnerable to cardiovascular morbidity and mortality and neither parathyroidectomy[@b67-dddt-10-2211] nor cinacalcet[@b68-dddt-10-2211] reduces the risk of death or major cardiovascular events in SHPT patients undergoing dialysis. Therefore, the timely management of SHPT at the initial stage may offer long-term survival in CKD patients. Several studies have proved the efficacy and safety of cinacalcet in stage 3 and 4 CKD patients with SHPT;[@b69-dddt-10-2211]--[@b72-dddt-10-2211] however, the noticeable PTH decrease followed by hypocalcaemia and hyperphosphatemia brought about the avoidance of cinacalcet prescription in CKD predialysis patients.[@b73-dddt-10-2211]--[@b75-dddt-10-2211] Since our findings in this study provided a potential target for the investigation of cinacalcet nonresponder group who have high possibility of parathyroidectomy or refractory SHPT, *CASR* SNPs may be useful biomarkers to administer cinacalcet in early stage of CKD patients to attain the individualized medical treatment of SHPT.

The main factors of cinacalcet resistance after several months or years of therapy are severely enlarged parathyroid gland (\>1 cm), nodular hyperplasia,[@b22-dddt-10-2211],[@b76-dddt-10-2211],[@b77-dddt-10-2211] and the downregulation of CaSR and VDR by uremic status which is resulted by inadequate dialysis.[@b78-dddt-10-2211] However, the parathyroid hyperplasia did not affect the cinacalcet nonresponsiveness in our short-term study as in previous studies.[@b79-dddt-10-2211],[@b80-dddt-10-2211] The dose of vitamin D was not different between two groups and findings from the study by Block et al[@b81-dddt-10-2211] presented that cinacalcet reduced PTH levels regardless of whether the vitamin D doses were increased, decreased, or unchanged. We performed multiple testing by Bonferroni correction and false discovery rate test. The result turned out that the association of rs1042636 or rs1802757 with PTH change was not significant. However, neither of these methods take into account the correlation of SNPs due to linkage disequilibrium, which tags the genetic variation across gene regions. Our result showed that the three SNPs of *CASR*, five SNPs of *VDR*, and three SNPs of *ALPL* comprise one haploblock each, representing that the SNPs are not independent and highly correlated. Thus, we rather not reflect the multiple testing in the results.

Our study has several limitations as follows. The first, 70 Korean patients are relatively small for genetic association study and diverse ethnic factors could not be considered. This limitation should warrant further large-scale studies to replicate and confirm our findings. The second, the included patients were on either hemodialysis or peritoneal dialysis; the Kt/V(K~urea~ ×T~d~/V~urea~) value which indicates the dialysis adequacy is not recirpocally conversed between two modalities, so the influence of dialysis could not be evaluated in our study. The third, we focused on the 3-month treatment of cinacalcet, and the result of long-term follow-up study on the mineral bone disease and cardiovascular disease could not be assessed. The last, most patients were on either phosphate binders or vitamin D analogs and the proportion of patients on either drug was not different between two groups, but the possible impact of different amount of concomitant calcium intake cannot be ruled out.

Conclusion
==========

We obtained supporting evidence for an association between cinacalcet response and *CASR* polymorphisms. We performed a comprehensive search for SNPs within genes associated with PTH regulations to find the precise frequencies and association with cinacalcet response in 70 dialytic SHPT patients for the first time in Korea. *CASR* SNPs rs1802757, rs1042636, and haplotypes of rs1042636, rs10190, and rs1802757 were significantly associated with cinacalcet response variance.

Supplementary materials
=======================

###### 

The primer sets and melting temperature (Tm) used for the SNaPshot assay

  Gene                                                      rs number                     Strand           Primer sequence         Tm                    
  --------------------------------------------------------- ----------------------------- ---------------- ----------------------- --------------------- ----
  *CASR*                                                    rs1042636                     Forward          Forward primer          CAGATGCAAGCAGAAGGT    55
  Reverse primer                                            CAAAGCTCTGTGAACTGGA                                                                          
  Genotyping primer                                         GCCTCAGAAGAAYKCCATGGCSCAC                                                                    
  rs2221266                                                 Reverse                       Forward primer   CTGTTTACCCCTGTTGGAT     55                    
  Reverse primer                                            TCCATTGTGTGCTACGTTT                                                                          
  Genotyping primer                                         GTGTGCTACGTTTGAGGTAAT                                                                        
  rs10190                                                   Reverse                       Forward primer   CCAAGAAAGATCCACCCTCA    55                    
  Reverse primer                                            TGGGCTAGGCAGTACAATCTG                                                                        
  Genotyping primer                                         atccacataagagctctgaggggaa                                                                    
  rs1802757                                                 Forward                       Forward primer   CCAAGAAAGATCCACCCTCA    55                    
  Reverse primer                                            TGGGCTAGGCAGTACAATCTG                                                                        
  Genotyping primer                                         ggagccagMgagacaRaccggggtt                                                                    
  *VDR*                                                     rs7975232                     Forward          Forward primer          aagtcactggagggcttt    55
  Reverse primer                                            TTAGCTTCATGCTGCACTC                                                                          
  Genotyping primer                                         TGGTGGGATTGAGCAGTGAGG                                                                        
  rs2228570                                                 Reverse                       Forward primer   gatgcaacatctgaaacca     55                    
  Reverse primer                                            AGCCTTCACAGGTCATAGC                                                                          
  Genotyping primer                                         agggaagtgctggccRccattKcctcc                                                                  
  rs1544410                                                 Forward                       Forward primer   CTACTTTGCTGGTTTGCAG     55                    
  Reverse primer                                            ATTGCCTCCAAAATCAATC                                                                          
  Genotyping primer                                         TTCCTGGRGCCACAGACAGRCCTGC                                                                    
  rs11574129                                                Forward                       Forward primer   TGTTCACCCACAGGGCTAA     55                    
  Reverse primer                                            CACAGCTTCCAGGAGTTGG                                                                          
  Genotyping primer                                         GAGTGATACAACTTCAAGTGCATGC                                                                    
  rs3847987                                                 Reverse                       Forward primer   CACCCAGCCCATTCTCTCT     55                    
  Reverse primer                                            GGGAAGAAAACCCACCTCA                                                                          
  Genotyping primer                                         AAGGGGGTGGGGTGGGAGCTGTGGG                                                                    
  rs739837                                                  Reverse                       Forward primer   CACCCAGCCCATTCTCTCT     55                    
  Reverse primer                                            GGGAAGAAAACCCACCTCA                                                                          
  Genotyping primer                                         CTCAACATCAGTCAGCAGCCACTTA                                                                    
  rs9729                                                    Forward                       Forward primer   agcaggtaccactgatttgga   60                    
  Reverse primer                                            gtctcgaactcccgacctc                                                                          
  Genotyping primer                                         TGCTAAACGAGTcaatcccMtcatt                                                                    
  *FGFR1*                                                   rs13317                       Forward          Forward primer          aattatccaggcatggtg    55
  Reverse primer                                            CCCAACAAATACAGTCTGGT                                                                         
  Genotyping primer                                         TCTATGTGGGCATGGTTTTGCC                                                                       
  *KL*                                                      rs1207568                     Reverse          Forward primer          CTCACCTAAGGGGGAATC    55
  Reverse primer                                            ACGCTCAGGTTCATTCTCT                                                                          
  Genotyping primer                                         cggggagaaaaggcgcSgaccaacttt                                                                  
  *RGS14*                                                   rs4074995                     Forward          Forward primer          GGAATGGAGAGAAGTGGAC   55
  Reverse primer                                            GAGGGTGGAAGAGCTGTAG                                                                          
  Genotyping primer                                         CATTTCATGCCAGCAGCTACGTTTCTC                                                                  
  *SLC34A1[\*](#tfn18-dddt-10-2211){ref-type="table-fn"}*   rs3812035                     Forward          Forward primer          CATCCCCTTTCTGGGACAG   55
  Reverse primer                                            ccaggTTGCAAGTCCTCAA                                                                          
  Genotyping primer                                         TCCCTTCCAACCTGTTCCCATTGAC                                                                    
  *ALPL*                                                    rs1697421                     Forward          Forward primer          TTGGAGTGCAGTGGTGTGA   55
  Reverse primer                                            GCAGCTCCCAAAGAAGAGG                                                                          
  Genotyping primer                                         CCCTTATGAGCACTTCTTAAAGGCA                                                                    
  rs3200254                                                 Forward                       Forward primer   ACCAGGCTGGGAAAGTGTC     55                    
  Reverse primer                                            TCTGGTATCCCCTCCAAGG                                                                          
  Genotyping primer                                         CACCTGGAAGAGCTTCAAACCGAGA                                                                    
  rs2242420                                                 Reverse                       Forward primer   ACTACGTCCCCCACGTGAT     60                    
  Reverse primer                                            CCTGGTGGTCTTGGAGTGA                                                                          
  Genotyping primer                                         AGAGGTAAGGAGATGGGAGTGGGA                                                                     
  rs2242421                                                 Forward                       Forward primer   ACTACGTCCCCCACGTGAT     60                    
  Reverse primer                                            CCTGGTGGTCTTGGAGTGA                                                                          
  Genotyping primer                                         CCTCTGGAACCCCCCAGGCCCTACA                                                                    
  rs1697405                                                 Reverse                       Forward primer   ACTACGTCCCCCACGTGAT     60                    
  Reverse primer                                            CCTGGTGGTCTTGGAGTGA                                                                          
  Genotyping primer                                         GGCCCCCACCTCCCTGCCCCTTGAK                                                                    
  rs1697406                                                 Forward                       Forward primer   ACTACGTCCCCCACGTGAT     60                    
  Reverse primer                                            CCTGGTGGTCTTGGAGTGA                                                                          
  Genotyping primer                                         CTGCAACTGCAAGAAAGGGGACCCA                                                                    
  *NR4A2*                                                   rs12803                       Reverse          Forward primer          GGCAGAGATAGCCGTGTGA   55
  Reverse primer                                            TGGGCTAGGCAGTACAATCTG                                                                        
  Genotyping primer                                         atccacataagagctctgaggggaa                                                                    
  *PTHLH*                                                   rs2796                        Forward          Forward primer          TGCTCTCAGCTGGGTTTTG   55
  Reverse primer                                            CATGATGCTGTTCTGCAGTGT                                                                        
  Genotyping primer                                         TCAGAATATTGTCTGCCTTAAAGCA                                                                    
  rs6253                                                    Forward                       Forward primer   TGCTCTCAGCTGGGTTTTG     55                    
  Reverse primer                                            CATGATGCTGTTCTGCAGTGT                                                                        
  Genotyping primer                                         TCTTCATAATTTGCTGGAGAAGTGT                                                                    
  rs6245                                                    Forward                       Forward primer   TGCTCTCAGCTGGGTTTTG     55                    
  Reverse primer                                            CATGATGCTGTTCTGCAGTGT                                                                        
  Genotyping primer                                         TCCAGCACCATAGAGAGGCGYTAGA                                                                    

**Note:**

SLC34A4 was not included in the final analysis because it didn't meet the Hardy Weinberg Equilibrium (HWE).

###### 

Association between biochemical parameters and the genotypes[\*](#tfn19-dddt-10-2211){ref-type="table-fn"} of four SNPs of *CASR*

  Parameter            Total Δ% (mean ± SD)   Δ% by genotypes, median (range)                                                                                                                  
  -------------------- ---------------------- --------------------------------- ----------------- ------------------ ----------------- ------------------ ----------------- ------------------ --------
  Ca mg/dL             −6.64                  −6.22                             −6.64             −6.27              −6.38             −6.27              −6.50             −5.75              −6.68
  (−19.09--15.81)      (−19.17--15.81)        (−25.67--5.07)                    (−25.67--5.07)    (−19.17--15.81)    (−25.67--5.07)    (−19.17--15.81)    (−25.67--5.07)    (−19.17--15.81)    
  *P*-value                                   0.622                                               0.889                                0.863                                0.590              
  P mg/dL              −8.13                  −3.87                             −9.35             −6.81              −9.23             −8.64              −9.84             −8.87              −9.23
  (−43.69--69.43)      (−69.23--72.44)        (−57.73--69.43)                   (−42.08--40.00)   (−69.23--72.44)    (−42.08--63.83)   (−69.23--72.44)    (−42.08--63.83)   (−69.23--72.44)    
  *P*-value                                   0.463                                               0.934                                0.714                                0.989              
  Ca × P mg^2^/dL^2^   −12.22                 −6.66                             −14.80            −9.82              −14.80            −12.73             −14.90            −13.68             −14.80
  (−44.87--68.70)      (−71.13--43.70)        (−64.98--68.70)                   (−48.81--30.50)   (−71.13--68.70)    (−48.81--41.24)   (−71.13--68.70)    (−48.81--41.24)   (−71.13--68.70)    
  *P*-value                                   0.686                                               0.874                                0.647                                0.862              
  ALP IU/l             2.36                   8.85                              2.35              2.04               2.36              0.69               6.67              0.91               5.14
  (−28.48--146.58)     (−29.26--84.42)        (−28.48--146.58)                  (−28.48--93.89)   (−29.26--146.58)   (−28.48--93.89)   (−29.26--146.58)   (−28.48--93.89)   (−29.26--146.58)   
  *P*-value                                   0.310                                               0.614                                0.197                                0.373              

**Note:**

Analyzed by a dominant genetic model.

**Abbreviations:** ALP, alkaline phosphatase; SD, standard deviation; SNP, single nucleotide polymorphism.
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###### 

Demographic characteristics at baseline for included subjects (n=70)

  Characteristics                                              Total (N=70)[\*](#tfn1-dddt-10-2211){ref-type="table-fn"} (%)   Grouped by cinacalcet response (N=68)[\*\*](#tfn2-dddt-10-2211){ref-type="table-fn"} (%)   *P*-value              
  ------------------------------------------------------------ --------------------------------------------------------------- ------------------------------------------------------------------------------------------ ---------------------- -----------
  Male sex, n (%)                                              32 (45.7)                                                       27 (50.9)                                                                                  4 (26.7)               0.096
  Age, years, median (range)                                   50 (21--75)                                                     49 (21--75)                                                                                52 (24--71)            0.325
  BMI, kg/cm^2^, median (range)                                22.37 (16.01--31.45)                                            22.08 (16.01--31.00)                                                                       23.29 (17.76--27.38)   0.206
  Cause of CKD, n (%)                                                                                                                                                                                                                            
   DM                                                          12 (17.2)                                                       7 (13.2)                                                                                   4 (26.7)               0.680
   HTN                                                         10 (14.3)                                                       7 (13.2)                                                                                   2 (13.3)               1.000
   GN                                                          28 (40.0)                                                       22 (41.5)                                                                                  6 (40.0)               0.916
   Others                                                      20 (28.6)                                                       17 (32.1)                                                                                  3 (20.0)               0.762
  Mode of dialysis, n (%)                                                                                                                                                                                                                        
   HD                                                          19 (27.1)                                                       11 (20.8)                                                                                  7 (46.7)               0.093
   PD                                                          40 (57.1)                                                       33 (62.3)                                                                                  6 (40.0)               0.124
   Both                                                        11 (15.7)                                                       9 (17.0)                                                                                   2 (13.3)               1.000
  Dialysis duration, median (range)                            97 (38--195)                                                    77.5 (15--300)                                                                             97 (38--195)           0.363
  Use of phosphate binder/calcium supplement, n (%)            62 (88.6)                                                       48 (90.6)                                                                                  14 (93.3)              1.000
  Lab values, median (range)                                                                                                                                                                                                                     
   iPTH (pg/mL)[\*](#tfn1-dddt-10-2211){ref-type="table-fn"}   620 (300--1,493)                                                622 (300--1,493)                                                                           601 (316--1,183)       0.375
   Albumin corrected calcium (mg/dL)                           9.84 (7.4--13.52)                                               9.72 (7.40--13.52)                                                                         10.50 (9.18--11.88)    **0.001**
   Phosphorus (mg/dL)                                          5.85 (3.40--12.80)                                              5.70 (3.50--12.80)                                                                         6.00 (3.40--7.50)      0.673
   Ca × P (mg^2^/dL^2^)                                        58.35 (32.41--94.72)                                            57.01 (32.41--94.72)                                                                       61.80 (37.38--71.10)   0.787
   ALP (IU/L)                                                  106 (41--393)                                                   100 (41--381)                                                                              124 (61--762)          0.252
   Hb (g/dL)                                                   10.50 (7.00--14.60)                                             10.70 (7.00--14.00)                                                                        10.10 (7.70--14.60)    0.107
   Albumin (g/dL)                                              3.80 (2.40--11.50)                                              3.80 (2.40--5.10)                                                                          3.90 (3.10--4.40)      0.953
   Serum creatinine (mg/dL)                                    11.69 (4.30--20.66)                                             12.03 (4.30--20.66)                                                                        10.85 (4.35--18.12)    0.248
   GFR (mL/min/1.73 m^2^)                                      3.80 (2.10--15.7)                                               3.80 (2.50--13.30)                                                                         3.80 (2.10--15.70)     0.842
  Comorbidity related with CKD-MBD, n (%)                                                                                                                                                                                                        
   Osteoporosis                                                6 (8.6)                                                         5 (9.4)                                                                                    1 (6.7)                1.000
   Osteopenia                                                  22 (31.4)                                                       18 (34.0)                                                                                  3 (20.0)               0.361
   Fracture                                                    11 (15.7)                                                       7 (13.2)                                                                                   4 (26.7)               0.243
   PTH hyperplasia or adenoma                                  15 (21.4)                                                       12 (22.6)                                                                                  3 (20.0)               0.726
   HTN                                                         51 (72.9)                                                       39 (73.6)                                                                                  10 (66.7)              0.745
   IHD, HF, AF, LVH                                            25 (35.7)                                                       16 (30.2)                                                                                  8 (53.3)               0.666
   Comorbidity related with neoplasm                           13 (18.6)                                                       7 (13.2)                                                                                   5 (33.3)               0.442

**Notes:**

A total of 70 patients were included in the final analysis.

A total of 68 patients who had available iPTH level were included in the cinacalcet response analysis. Significant results are marked in bold.

**Abbreviations:** AF, atrial fibrillation; ALP, alkaline phosphatase; BMI, body mass index; CKD, chronic kidney disease; CKD-MBD, chronic kidney disease-mineral bone disease; DM, diabetes mellitus; GFR, glomerular filtration rate; Hb, hemoglobin; HF, heart failure; HTN, hypertension; GN, glomerulonephritis; HD, hemodialysis; IHD, ischemic heart disease; iPTH, intact parathyroid hormone; LVH, left ventricular hypertrophy; PD, peritoneal dialysis; PTH, parathyroid hormone.

###### 

Comparison of biochemical parameter percent changes between baseline and 3-month treatment with cinacalcet (n=68)

  Parameter               Responders Median (range) (%)   Nonresponders Median (range) (%)   *P*-value[\*](#tfn5-dddt-10-2211){ref-type="table-fn"}
  ----------------------- ------------------------------- ---------------------------------- --------------------------------------------------------
  ΔPTH (pg/mL)            −42.29 (−97.41--\[−9.23\])      6.16 (0.90--45.25)                 \<**0.001**
  ΔCalcium (mg/dL)        −5.75 (−25.67--15.81)           −7.13 (−19.09--1.67)               0.182
  ΔPhosphorus (mg/dL)     −9.84 (−69.23--69.43)           −8.42 (−33.33--72.43)              0.170
  ΔCa × P (mg^2^/dL^2^)   −14.70 (−71.13--68.70)          −8.84 (−36.99--43.70)              0.296
  ΔALP (IU/L)             1.60 (−28.48--146.58)           10.71 (−29.26--93.89)              0.211

**Notes:** The 3-month treatment value for biochemical parameters is defined as the mean value during baseline to 3-month treatment.

Descriptive *P*-values were obtained from the independent-samples *t*-test or Mann--Whitney *U*-test. Significant results are marked in bold.

**Abbreviations:** ALP, alkaline phosphatase; PTH, parathyroid hormone.

###### 

The loci and minor allele frequency (MAF) information of the 24 SNPs in *CASR*, *VDR*, *FGFR1*, *KL*, *RGS14*, *SLC34A1*, *ALPL*, *NR4A2*, and *PTHLH* genes

  Gene/SNP                                                 Chromosome position   Alleles   SNP location   Observed MAF/expected MAF   HWE test (*P*-value)
  -------------------------------------------------------- --------------------- --------- -------------- --------------------------- ----------------------
  *CASR*                                                                                                                              
   rs1042636                                               3:122284922           A/G       Exon           0.458/0.2065                0.59
   rs2221266                                               3:122277969           C/T       Intron         0.410/0.4619                0.97
   rs10190                                                 3:122286389           C/T       3′UTR          0.387/0.4669                0.81
   rs1802757                                               3:122286284           C/T       3′UTR          0.359/0.1983                0.43
  *VDR*                                                                                                                               
   rs7975232                                               12:47845054           A/C       Intron         0.160/0.4846                0.87
   rs2228570                                               12:47879112           C/T       Exon           0.382/0.3285                0.80
   rs1544410                                               12:47846052           A/G       Intron         0.063/0.2959                0.57
   rs11574129                                              12:47843520           T/C       3′UTR          0.099/0.0385                0.08
   rs3847987                                               12:47844285           G/T       3′UTR          0.106/0.1288                0.13
   rs739837                                                12:47844438           C/A       3′UTR          0.176/0.4942                0.67
   rs9729                                                  12:47842840           C/A       3′UTR          0.169/0.4902                0.71
  *FGFR1*                                                                                                                             
   rs13317                                                 8:38411996            C/T       3′UTR          0.345/0.2250                0.06
  *KL*                                                                                                                                
   rs1207568                                               13:33016046           C/T       Exon           0.160/0.1601                0.11
  *RGS14*                                                                                                                             
   rs4074995                                               5:177370342           A/G       Intron         0.236/0.1895                0.20
  *SLC34A1[\*](#tfn7-dddt-10-2211){ref-type="table-fn"}*                                                                              
   rs3812035                                               5:177390142           A/C       3′UTR          0.255/0.387                 **0.01**
  *ALPL*                                                                                                                              
   rs1697421                                               1:21496799            A/G       Exon           0.458/0.3776                0.50
   rs3200254                                               1:21568242            C/T       Exon           0.424/0.2670                0.66
   rs2242420                                               1:21578036            C/T       3′UTR          0.155/0.1172                0.47
   rs2242421                                               1:21578081            A/G       3′UTR          0.345/0.2220                0.46
   rs1697405                                               1:21577713            G/A       3′UTR          0.268/0.3367                0.43
   rs1697406                                               1:21577774            A/G       3′UTR          0.148/0.1318                0.49
  *NR4A2*                                                                                                                             
   rs12803                                                 2:156329935           G/A       3′UTR          0.2863/0.169                0.45
  *PTHLH*                                                                                                                             
   rs2796                                                  12:27963178           A/G       3′UTR          0.127/0.0727                0.76
   rs6253                                                  12:27963008           A/G       3′UTR          0.394/0.3243                0.09
   rs6245                                                  12:27963124           A/G       3′UTR          0.085/0.0629                0.40

**Note:**

Hardy--Weinberg Equilibrium (HWE) test was not satisfied and *SLC34A1* rs3812035 excluded for our analysis. Significant results are marked in bold.

**Abbreviations:** UTR, untranslated region; SNP, single nucleotide polymorphism; MAF, minor allele frequency.

###### 

Comparisons of genotypes and allele frequencies between responders versus nonresponders group

  Gene/SNP                                                          Genotype frequency (%)   Minor allele frequency (%)                             
  ----------------------------------------------------------------- ------------------------ ---------------------------- ----------- ------ ------ -------
  *CASR*                                                                                                                                            
   rs1042636 (A/G)                                                  15.1/50.9/34.0           40/53.3/6.7                  **0.036**   59.4   33.3   0.075
   rs2221266 (C/T)                                                  41.5/45.3/13.2           13.3/53.3/33.3               0.086       35.8   60.0   0.111
   rs10190[\#](#tfn10-dddt-10-2211){ref-type="table-fn"} (C/T)      42.3/44.2/13.5           15.4/61.5/23.1               0.190       35.6   53.8   0.149
   rs1802757[\#](#tfn10-dddt-10-2211){ref-type="table-fn"} (C/T)    44.2/48.1/7.7            15.4/61.5/23.1               0.086       31.7   53.8   0.085
  *VDR*                                                                                                                                             
   rs7975232 (G/T)                                                  66.0/28.3/3.8            80/20/0                      0.336       17.9   10     0.292
   rs2228570 (C/T)                                                  37.7/47.2/15.1           33.3/60.0/6.7                0.585       38.7   36.7   0.920
   rs1544410 (A/G)                                                  84.9/15.1/0              93.3/6.7/0                   0.672       7.5    3.3    1.000
   rs11574129[\#](#tfn10-dddt-10-2211){ref-type="table-fn"} (T/C)   82.7/13.5/3.8            84.6/15.4/0                  0.574       10.5   7.7    1.000
   rs3847987[\#](#tfn10-dddt-10-2211){ref-type="table-fn"} (G/T)    78.8/15.4/3.8            84.6/15.4/0                  0.706       11.5   7.7    0.672
   rs739837[\#](#tfn10-dddt-10-2211){ref-type="table-fn"} (C/A)     61.5/32.7/3.8            76.9/23.1/0                  0.762       20.2   11.5   1.000
   rs9729[\#](#tfn10-dddt-10-2211){ref-type="table-fn"} (C/A)       63.5/30.8/3.8            76.9/23.1/0                  0.769       19.2   11.5   1.000
  *FGFR1*                                                                                                                                           
   rs13317 (G/A)                                                    47.2/39.6/13.2           46.7/20.0/33.3               0.313       33.0   43.3   0.865
  *KL*                                                                                                                                              
   rs1207568 (C/T)                                                  66.0/32.1/1.9            66.7/33.3/0                  0.865       17.0   20.0   0.852
  *RGS14*                                                                                                                                           
   rs4074995 (A/G)                                                  50.9/30.2/11.3 (F:7.6)   60.0/33.3/6.7                0.828       26.4   23.3   1.000
  *ALPL*                                                                                                                                            
   rs1697421 (A/G)                                                  34.0/41.5/24.5           6.7/46.7/26.7                0.491       45.3   50.0   0.666
   rs3200254 (C/T)                                                  30.2/45.3/24.5           26.7/53.3/6.7 (F:13.3)       0.837       47.2   33.3   0.818
   rs2242420[\#](#tfn10-dddt-10-2211){ref-type="table-fn"} (C/T)    65.4/32.7/1.9            76.9/23.1/0                  0.880       18.3   11.5   1.000
   rs2242421[\#](#tfn10-dddt-10-2211){ref-type="table-fn"} (A/G)    42.3/42.3/15.4           46.2/38.5/15.4               0.964       36.5   34.6   0.955
   rs1697405[\#](#tfn10-dddt-10-2211){ref-type="table-fn"} (G/A)    51.9/42.3/5.8            46.2/38.5/7.7                0.920       26.9   26.9   1.000
   rs1697406[\#](#tfn10-dddt-10-2211){ref-type="table-fn"} (A/G)    67.3/30.8/1.9            69.2/23.1/0 (F:7.7)          0.858       17.3   11.5   1.000
  *NR4A2*                                                                                                                                           
   rs12803 (G/A)                                                    69.2/28.8/1.9            61.5/38.5/0                  0.721       16.3   19.2   0.704
  *PTHLH*                                                                                                                                           
   rs2796[\#](#tfn10-dddt-10-2211){ref-type="table-fn"} (A/G)       73.1/25.0/1.9            84.6/15.4/0                  0.589       14.4   7.7    0.672
   rs6253[\#](#tfn10-dddt-10-2211){ref-type="table-fn"} (A/G)       32.7/51.9/15.4           23.1/76.9/0                  0.296       41.3   38.5   0.656
   rs6245[\#](#tfn10-dddt-10-2211){ref-type="table-fn"} (A/G)       80.8/19.2/0              92.3/7.7/0                   0.439       9.6    3.8    1.000

**Notes:** Significant result is marked with bold type. F means failure rate (%) to genotype analysis.

SNPs are located in 3′ untranslated region and analyzed in 65 patients (responder: 52, nonresponder: 13).

**Abbreviations:** AA, homozygote major allele; AB, heterozygote allele; BB, homozygote minor allele; SNP, single nucleotide polymorphism.

###### 

Association of PTH regulation by cinacalcet with SNPs of *CASR*, *VDR*, *FGFR1*, *KL*, *ALPL*, *RGS14*, *NR4A2*, and *PTHLH*

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene/SNP            Genotype model[\*](#tfn13-dddt-10-2211){ref-type="table-fn"}   Dominant model[\*\*](#tfn14-dddt-10-2211){ref-type="table-fn"}   Recessive model[\*\*](#tfn14-dddt-10-2211){ref-type="table-fn"}                               
  ------------------- -------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------- --------------------------- ------------------------
  *CASR*                                                                                                                                                                                                                                            

   rs1042636 (A/G)    **0.074 (0.008--0.721)**\                                      0.395 (0.106--1.479)\                                            1                                                                 **0.267 (0.074--0.957**)\   0.139 (0.017--1.142)\
                      ***P***=**0.025**                                              *P*=0.168                                                                                                                          ***P***=**0.035**           *P*=0.050

   rs2221266 (C/T)    5.500 (0.839--36.059)\                                         3.826 (0.730--20.044)\                                           1                                                                 4.613 (0.945--22.526)\      2.813 (0.758--10.431)\
                      *P*=0.076                                                      *P*=0.112                                                                                                                          *P*=0.065                   *P*=0.142

   rs10190 (C/T)      5.500 (0.741--40.803)\                                         4.304 (0.730--20.044)\                                           1                                                                 4.033 (0.811--20.056)\      1.929 (0.423--8.784)\
                      *P*=0.095                                                      *P*=0.112                                                                                                                          *P*=0.109                   *P*=0.405

   rs1802757 (C/T)    **8.625 (1.077--69.075)**\                                     3.680 (0.707--19.156)\                                           1                                                                 4.362 (0.878--21.669)\      3.600 (0.695--18.646)\
                      ***P***=**0.042**                                              *P*=0.122                                                                                                                          *P*=0.056                   *P*=0.136

  *VDR*                                                                                                                                                                                                                                             

   rs7975232 (G/T)                                                                   0.365 (0.073--1.823)\                                            1                                                                 0.324 (0.065--1.607)\       
                                                                                     *P*=0.219                                                                                                                          *P*=0.200                   

   rs2228570 (C/T)    0.500 (0.050--4.978)\                                          1.440 (0.416--4.983)\                                            1                                                                 1.212 (0.362--4.059)\       0.402 (0.046--3.497)\
                      *P*=0.554                                                      *P*=0.565                                                                                                                          *P*=0.755                   *P*=0.672

   rs1544410 (A/G)                                                                   0.402 (0.046--3.497)\                                            1                                                                 0.402 (0.046--3.497)\       
                                                                                     *P*=0.409                                                                                                                          *P*=0.672                   

   rs11574129 (T/C)                                                                  0.438 (0.050--3.853)\                                            1                                                                 0.350 (0.041--3.015)\       
                                                                                     *P*=0.456                                                                                                                          *P*=0.439                   

   rs3847987 (G/T)                                                                   0.741 (0.141--3.905)\                                            1                                                                 0.606 (0.118--3.121)\       
                                                                                     *P*=0.723                                                                                                                          *P*=0.717                   

   rs739837 (C/A)                                                                    0.917 (0.245--3.433)\                                            1                                                                 0.815 (0.220--3.021)\       
                                                                                     *P*=0.897                                                                                                                          *P*=1.000                   

   rs9729 (C/A)                                                                      1.007 (0.268--3.791)\                                            1                                                                 0.889 (0.239--3.307)\       
                                                                                     *P*=0.991                                                                                                                          *P*=1.000                   

  *FGFR1*                                                                                                                                                                                                                                           

   rs13317 (C/T)      1.500 (0.355--6.347)\                                          0.429 (0.100--1.828)\                                            1                                                                 0.724 (0.229--2.286)\       2.045 (0.520--8.044)\
                      *P*=0.582                                                      *P*=0.252                                                                                                                          *P*=0.581                   *P*=0.442

  *KL*                                                                                                                                                                                                                                              

   rs1207568 (C/T)                                                                   1.029 (0.304--3.486)\                                            1                                                                 0.972 (0.289--3.276)\       
                                                                                     *P*=0.963                                                                                                                          *P*=0.964                   

  *RGS14*                                                                                                                                                                                                                                           

   rs4074995 (A/G)    0.500 (0.053--4.732)\                                          0.938 (0.267--3.292)\                                            1                                                                 0.818 (0.252--2.653)\       0.512 (0.057--4.626)\
                      *P*=0.546                                                      *P*=0.920                                                                                                                          *P*=0.738                   *P*=1.000

  *ALPL*                                                                                                                                                                                                                                            

   rs1697421 (A/G)    1.821 (0.266--12.473)\                                         2.705 (0.497--14.718)\                                           1                                                                 2.361 (0.465--11.979)\      0.929 (0.220--3.928)\
                      *P*=0.541                                                      *P*=0.250                                                                                                                          *P*=0.484                   *P*=1

   rs3200254 (C/T)    0.667 (0.104--4.261)\                                          1.120 (0.282--4.449)\                                            1                                                                 0.973 (0.261--3.627)\       0.621 (0.121--3.197)\
                      *P*=0.668                                                      *P*=0.872                                                                                                                          *P*=1.000                   *P*=0.718

   rs2242420 (C/T)                                                                   0.972 (0.260--3.632)\                                            1                                                                 0.915 (0.246--3.400)\       
                                                                                     *P*=0.967                                                                                                                          *P*=1.000                   

   rs2242421 (A/G)    0.917 (0.153--5.508)\                                          0.833 (0.221--3.138)\                                            1                                                                 0.856 (0.252--2.902)\       1.000 (0.186--5.390)\
                      *P*=0.924                                                      *P*=0.788                                                                                                                          *P*=0.802                   *P*=1.000

   rs1697405 (G/A)    1.500 (0.132--17.037)\                                         1.227 (0.347--4.343)\                                            1                                                                 1.080 (0.308--3.791)\       1.485 (0.141--15.659)\
                      *P*=0.744                                                      *P*=0.751                                                                                                                          *P*=0.904                   *P*=0.574

   rs1697406 (A/G)                                                                   1.200 (0.313--4.596)\                                            1                                                                 0.686 (0.164--2.866)\       
                                                                                     *P*=0.790                                                                                                                          *P*=0.739                   

  *NR4A2*                                                                                                                                                                                                                                           

   rs12803 (G/A)                                                                     1.500 (0.422--5.338)\                                            1                                                                 1.250 (0.361--4.327)\       
                                                                                     *P*=0.531                                                                                                                          *P*=0.724                   

  *PTHLH*                                                                                                                                                                                                                                           

   rs2796 (A/G)                                                                      0.487 (0.096--2.472)\                                            1                                                                 0.452 (0.090--2.280)\       
                                                                                     *P*=0.385                                                                                                                          *P*=0.488                   

   rs6253 (A/G)                                                                      1.286 (0.341--4.853)\                                            1                                                                 1.000 (0.268--3.732)\       
                                                                                     *P*=0.711                                                                                                                          *P*=1.000                   

   rs6245 (A/G)                                                                      0.350 (0.041--3.015)\                                            1                                                                 0.350 (0.041--3.015)\       
                                                                                     *P*=0.339                                                                                                                          *P*=0.439                   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Significant results are marked in bold type.

Logistic regression analysis.

Chi-square analysis.

**Abbreviations:** AA, homozygote major allele; AB, heterozygote; BB, homozygote minor allele; CI, confidence interval; OR, odds ratio; PTH, parathyroid hormone; SNP, single nucleotide polymorphism.

###### 

Association of PTH regulation by cinacalcet with *CASR*, *VDR*, and *ALPL* haplotypes

  Gene/SNP            Haplotype   Haplotype frequency (%)   Case/control frequencies (%)   OR (95% CI)                *P*-value
  ------------------- ----------- ------------------------- ------------------------------ -------------------------- -----------
  *CASR*                                                                                                              
   rs1042636 (A/G)    GCC         0.529                     33.3/58.5                      **0.355** (0.151--0.832)   **0.015**
   rs1802757 (C/T)    ATT         0.375                     57.3/31.9                      **2.769** (1.208--6.347)   **0.014**
   rs10190 (C/T)      ACC         0.064                     8.5/5.8                        1.786 (0.420--7.597)       0.423
  ACT                 0.032       0.9/3.8                   --                             0.575                      
  *VDR*                                                                                                               
   rs9729 (C/A)       CTGCG       0.815                     88.5/79.8                      1.940 (0.531--7.081)       0.404
   rs11574129 (T/C)   ACTAT       0.092                     7.7/9.6                        0.783 (0.161--3.814)       1
   rs3847987 (G/T)    ATGAT       0.068                     3.8/7.6                        0.480 (0.057--4.019)       0.686
   rs739837 (C/A)                                                                                                     
   rs7975232 (G/T)                                                                                                    
  *ALPL*                                                                                                              
   rs1697406 (A/G)    GCG         0.638                     65.4/63.5                      1.088 (0.442--2.678)       0.855
   rs2242420 (C/T)    GCA         0.192                     23.1/18.3                      1.342 (0.475--3.794)       0.578
   rs2242421 (A/G)    ATA         0.162                     11.5/17.3                      0.623 (0.169--2.300)       0.567

**Note:** Significant results are marked in bold type.

**Abbreviations:** CI, confidence interval; OR, odds ratio; PTH, parathyroid hormone; SNP, single nucleotide polymorphism.
